Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives $15.40 Consensus Price Target from Brokerages

Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) have received a consensus rating of “Buy” from the seven analysts that are covering the firm, Marketbeat reports. Seven research analysts have rated the stock with a buy recommendation. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $15.40.

Several brokerages recently issued reports on TNYA. Chardan Capital reiterated a “buy” rating and issued a $20.00 price target on shares of Tenaya Therapeutics in a report on Thursday, March 21st. Canaccord Genuity Group decreased their price objective on shares of Tenaya Therapeutics from $19.00 to $18.00 and set a “buy” rating for the company in a research report on Wednesday, March 20th. Finally, HC Wainwright reissued a “buy” rating and issued a $18.00 price objective on shares of Tenaya Therapeutics in a research report on Tuesday, March 19th.

Insider Buying and Selling at Tenaya Therapeutics

In related news, major shareholder Group Gp Lp Column III purchased 2,222,222 shares of Tenaya Therapeutics stock in a transaction dated Monday, February 12th. The shares were acquired at an average price of $4.50 per share, with a total value of $9,999,999.00. Following the completion of the transaction, the insider now owns 13,599,275 shares of the company’s stock, valued at approximately $61,196,737.50. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, major shareholder Group Gp Lp Column III purchased 2,222,222 shares of Tenaya Therapeutics stock in a transaction dated Monday, February 12th. The shares were acquired at an average price of $4.50 per share, with a total value of $9,999,999.00. Following the completion of the transaction, the insider now owns 13,599,275 shares of the company’s stock, valued at approximately $61,196,737.50. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Timothy Hoey sold 4,681 shares of the stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $5.86, for a total transaction of $27,430.66. Following the transaction, the insider now directly owns 242,715 shares in the company, valued at approximately $1,422,309.90. The disclosure for this sale can be found here. Insiders sold a total of 20,908 shares of company stock valued at $122,867 in the last ninety days. Insiders own 33.83% of the company’s stock.

Hedge Funds Weigh In On Tenaya Therapeutics

Large investors have recently bought and sold shares of the business. Balyasny Asset Management LLC bought a new position in Tenaya Therapeutics in the third quarter worth about $29,000. Millennium Management LLC bought a new position in Tenaya Therapeutics in the second quarter worth about $65,000. California State Teachers Retirement System lifted its holdings in Tenaya Therapeutics by 62.2% in the first quarter. California State Teachers Retirement System now owns 12,208 shares of the company’s stock worth $144,000 after acquiring an additional 4,682 shares during the last quarter. Jane Street Group LLC bought a new position in Tenaya Therapeutics in the fourth quarter worth about $25,000. Finally, Tower Research Capital LLC TRC lifted its holdings in Tenaya Therapeutics by 162.8% in the third quarter. Tower Research Capital LLC TRC now owns 12,891 shares of the company’s stock worth $33,000 after acquiring an additional 7,986 shares during the last quarter. Institutional investors own 90.54% of the company’s stock.

Tenaya Therapeutics Trading Down 3.6 %

Shares of NASDAQ TNYA opened at $4.30 on Friday. Tenaya Therapeutics has a 12-month low of $1.66 and a 12-month high of $8.09. The company has a market cap of $337.62 million, a P/E ratio of -2.57 and a beta of 2.60. The stock has a fifty day moving average price of $5.29 and a 200 day moving average price of $3.57.

Tenaya Therapeutics (NASDAQ:TNYA) last announced its quarterly earnings results on Monday, March 18th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.05. On average, sell-side analysts forecast that Tenaya Therapeutics will post -1.7 EPS for the current fiscal year.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.